Press Release

– Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation –– Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing additional clinical validation of its mechanism of action –   NEW ORLEANS and CAMBRIDGE, UK, October 25, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that […]

NEW ORLEANS and CAMBRIDGE, UK, October 17, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will present the previously announced Phase 2a trial data evaluating its immune-resetting drug candidate, ‘1104, in

The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoE NEW ORLEANS and CAMBRIDGE, UK, September 21, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced

NEW ORLEANS and CAMBRIDGE, UK, August 8, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced it will host a virtual KOL event on ‘1104, a first-in-class peptide for eosinophilic esophagitis (EoE) and allergen

– Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo – – Unique broad mechanistic effect across a range of key cell types associated with EoE – – Novel findings across a range of immune cells that differentiates ‘1104 from other therapies – NEW ORLEANS and CAMBRIDGE, UK, July 18, 2023 –

Data demonstrates the potential of ‘1805 to reset the immune system through its unique mechanism of action across various autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis NEW ORLEANS and CAMBRIDGE, UK, June 5, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior

Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond NEW ORLEANS and CAMBRIDGE, UK, May 22, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with

NEW ORLEANS and CAMBRIDGE, UK, May 10, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will present at two medical meetings in May: the American Thoracic Society (ATS) International Conference

– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive impact on an array of histological measures of EoE – – Favorable safety and tolerability profile consistent with Phase 1 trial results – NEW ORLEANS and CAMBRIDGE, UK, April 19 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company

NEW ORLEANS, LA and CAMBRIDGE, England, April 13, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that management will be presenting at the 8th Food Allergy Fund Summit being held on